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ARTICLE OPEN
Non-motor correlates of wrist-worn wearable sensor use in
Parkinson’s disease: an exploratory analysis
Daniel J. van Wamelen 1,2,3*, Shweta Hota 1, Aleksandra Podlewska1,2,4, Valentina Leta1,2,5, Dhaval Trivedi1,2, Alexandra Rizos2,
Miriam Parry1,2 and K. Ray Chaudhuri1,2
Wearable sensors are becoming increasingly more available in Parkinson’s disease and are used to measure motor function.
Whether non-motor symptoms (NMS) can also be measured with these wearable sensors remains unclear. We therefore performed
a retrospective, exploratory, analysis of 108 patients with a diagnosis of idiopathic Parkinson’s disease enroled in the Non-motor
Longitudinal International Study (UKCRN No. 10084) at King’s College Hospital, London, to determine the association between the
range and nature of NMS and an accelerometer-based outcome measure of bradykinesia (BKS) and dyskinesia (DKS). NMS were
assessed by the validated NMS Scale, and included, e.g., cognition, mood and sleep, and gastrointestinal, urinary and sexual
problems. Multiple linear regression modelling was used to identify NMS associated with BKS and DKS. We found that BKS was
associated with domains 6 (gastrointestinal tract; p= 0.006) and 8 (sexual function; p= 0.003) of the NMS scale. DKS was associated
with domains 3 (mood/cognition; p= 0.016), 4 (perceptual problems; p= 0.025), 6 (gastrointestinal tract; p= 0.029) and 9
(miscellaneous, p= 0.003). In the separate domains, constipation was signiﬁcantly associated with BKS. Delusions, dysphagia,
hyposmia, weight change and hyperhidrosis were identiﬁed as signiﬁcantly associated with DKS. None of the NMSS domains were
associated with disease duration (p ≥ 0.08). In conclusion, measures of BKS and DKS were mainly associated with gastrointestinal
problems, independent of disease duration, showing the potential for wearable devices to pick up on these symptoms. These
exploratory results deserve further exploration, and more research on this topic in the form of comprehensive large-scale studies is
needed.
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INTRODUCTION
Current PD management guidelines focus predominantly on
treating motor symptoms and evidence for the treatment of non-
motor symptoms (NMS) is lagging behind the treatment of motor
symptoms.1,2 Addressing NMS is crucial as some can present
15–20 years before the onset of motor symptoms and impact
greatly on quality of life.3,4 Moreover, there is a clear need for
objective monitoring of NMS as many of these symptoms are
unreported by up to 42.8% of NMS that were undeclared by PD
patients in the clinic, which were later identiﬁed by the NMS
Questionnaire.5
The Parkinson’s KinetiGraph™ (PKG), developed by Global
Kinetics Corporation, is a wrist-worn wearable sensor device that
uses an accelerometer to provide continuous ambulatory mon-
itoring of movement.6 The device is worn on the primarily affected
arm and produces bradykinesia (BKS) and dyskinesia (DKS) scores
every 2 min, which are plotted over several days to create a
graphical representation of the patient’s motor control.6 The PKG
algorithms for BKS and DKS have been validated against the
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS) Part III and IV,
and the Abnormal Involuntary Movement Scale (AIMS).7 The
device has MHRA and FDA–CEA marking, and is one of the recent
objective wearables measuring BKS and DKS in PD.7,8
Wearable sensor devices measuring motor outcomes have
previously been used to identify associations with NMS in PD.8–12
A study using wrist-worn actigraph monitors found that circadian
rest-activity rhythms were associated with cognitive performance,
independent of sleep.13 In addition, the PKG has already been
utilised to measure NMS in a clinical setting. There are data to
support its efﬁcacy to address impulse control disorder and sleep
disorders in PD.9–12 Periods of immobility measured by the PKG
were in concordance with the detection of sleep by daytime
polysomnography, suggesting that ‘percentage time immobile’
could be a measure of daytime sleepiness in PD.11 Similarly, a
conditioned response to acknowledge the consumption of
medication on the PKG device has been associated with high
impulsive–compulsive behaviour scores.10 In the current study, we
aim to explore other non-motor correlates of the PKG.
RESULTS
Patient characteristics
A total of 108 participants (72 male and 36 female) for whom a
PKG readout was available were included in the analysis. In our
centre, we provide wearable sensor monitoring to all patients who
are willing to use the PKG watch for six consecutive days. Patients
were not selected based on the presence of motor ﬂuctuations,
and their baseline non-motor characteristics did not differ from
patients participating in the NILS study who did not receive a PKG
(p= 0.91), making a selection bias unlikely. In total, 80 participants
had a PKG recording within 30 days of their clinical assessment
(74.1%), 6.5% between 31 and 60 days, 9.3% between 61 and
90 days, and 10.2% between 91 and 120 days. Participant
demographics are summarised in Table 1.
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Bradykinesia
A multiple linear regression model was created with the BKS score
as the dependent variable and disease duration, age of onset,
LEDD, NMSS domains 1–9, MMSE, HADS, PDSS and ESS scores as
independent variables (Table 2). The results of the regression
indicated that the predictors explained 24.8% of the variance in
the model (adjusted R2= 0.248, SE= 7.23). BKS was predicted by
NMSS domain 6 (gastrointestinal tract; β= 0.303, p= 0.006), NMSS
domain 8 (sexual function; β= 0.301, p= 0.003) and LEDD (β=
−0.327, p= 0.001). After exclusion of patients on apomorphine
and levodopa intestinal infusion therapy, this was the only NMSS
domain 6 (β= 0.389, p= 0.008, other dependent variables p >
0.09) in patients on oral therapies (n= 80).
In order to control for the possible effect of NMS changes over
time, we performed a separate analysis for patients who had the
start of the PKG recording taking place within 30 days of their
clinical assessment (n= 80). This model (adjusted R2= 0.436, SE=
7.28) conﬁrmed that BKS was predicted by NMSS domain 6
(gastrointestinal tract; β= 0.241, p= 0.042), NMSS domain 8
(sexual function; β= 0.304, p= 0.010) and LEDD (β=−0.398,
p= 0.001).
To further clarify which speciﬁc NMS predicted BKS, we
performed multiple linear regression with the speciﬁc items
within NMSS domains 6 and 8 added as independent variables.
We observed that only item 21 (constipation) was a signiﬁcant
predictor of BKS (β= 0.311, p= 0.001).
When the same linear regression was repeated, but with SCOPA
motor scores as the dependent variable, again only gastrointest-
inal symptoms were identiﬁed as the only signiﬁcant predictor
(p= 0.045; model R2= 0.30). Moreover, none of the NMSS
domains showed a signiﬁcant association with disease duration
(p ≥ 0.08).
Dyskinesia
A multiple linear regression model was created with the DKS score
as the dependent variable and the aforementioned demographic
and non-motor-scale predictors as independent variables (Table 2).
The predictors explained 33.2% of the variance in the model
(adjusted R2= 0.332, Std. error= 10.51). DKS was predicted by
NMSS domain 3 (mood/cognition; β=−0.308, p= 0.016), NMSS
domain 4 (perceptual problems/hallucinations; β= 0.229, p=
0.025), NMSS domain 6 (gastrointestinal tract; β=−0.247, p=
0.029), NMSS domain 9 (miscellaneous; β= 0.332, p= 0.003) and
total LEDD (β= 0.258, p= 0.016). In patients on oral therapies
(n= 80), DKS was predicted by NMSS domain 4 (β=−0.262, p=
0.037), NMSS domain 6 (β=−0.406, p= 0.002) and NMSS domain
9 (β= 0.259, p= 0.048), but not by LEDD (β= 0.151, p= 0.19).
In order to determine which particular NMS within the
aforementioned domains were signiﬁcant in predicting DKS, a
second multiple linear regression model was created, with the
Table 1. Participant demographics and non-motor scales and
questionnaires
Mean SD Range
Age (years) 62.8 9.4 38.0–82.0
Age at onset (years) 55.3 9.1 35.0–77.0
Disease duration (years) 7.5 5.5 0.0–26.0
Hoehn and Yahr stage 2.9 1.0 2–4
LEDD (mg) 950.4 673.8 0–2818
SCOPA
Motor score 10.9 5.7 0–30
Activities of daily living 6.2 4.3 0–20
Motor complications 2.5 2.6 0–11
Parkinson’s Kinetigraph measures
Bradykinesia score 27.0 8.7 6.9–52.9
Dyskinesia score 5.6 12.9 0.0–84.7
NMSS
Total scores 57.2 37.8 0–161
1. Cardiovascular 1.8 3.1 0–16
2. Sleep/fatigue 12.0 8.7 0–36
3. Mood/cognition 9.2 11.3 0–48
4. Perceptual/hallucinations 2.3 5.3 0–32
5. Attention/memory 6.7 8.6 0–36
6. Gastrointestinal tract 5.0 5.9 0–24
7. Urinary 7.2 9.1 0–36
8. Sexual function 2.5 5.5 0–24
9. Miscellaneousa 10.4 7.6 0–36
PDSS score 98.2 25.9 34–149
HADS (anxiety) score 7.5 4.3 0–18
HADS (depression) score 6.4 3.9 0–19
MMSE score 28.2 3.6 23–30
ESS score 9.1 5.4 0–23
SCOPA Scales for Outcomes in Parkinson’s Disease, LEDD levodopa
equivalent dose, NMSS non-motor symptom scale, PDSS Parkinson’s disease
sleep scale, HADS hospital and anxiety depression scale, MMSE mini mental
state examination, ESS Epworth’s sleep scale, PKG Parkinson’s KinetiGraph,
BKS bradykinesia score, DKS dyskinesia score
aThe miscellaneous domain contains questions about pain, hyposmia,
hyperhidrosis and weight change
Table 2. Multiple linear regression model of bradykinesia and
dyskinesia non-motor predictors deﬁned by the non-motor symptom
scale domains
BKS DKS
β P β P
Disease duration 0.047 0.62 0.088 0.36
Age 0.072 0.45 0.036 0.71
NMSS cardiovascular −0.080 0.44 0.065 0.54
NMSS sleep/fatigue −0.006 0.96 0.083 0.52
NMSS mood/cognition 0.075 0.54 −0.308 0.016
NMSS perceptual/hallucinations −0.055 0.58 0.229 0.025
NMSS attention/memory −0.102 0.34 −0.055 0.62
NMSS gastrointestinal tract 0.303 0.006 −0.247 0.029
NMSS urinary 0.100 0.37 0.024 0.83
NMSS sexual function 0.301 0.003 0.005 0.96
NMSS miscellaneousa −0.182 0.09 0.322 0.003
PDSS 0.182 0.11 0.059 0.61
HADS −0.009 0.95 0.144 0.29
MMSE −0.029 0.76 −0.116 0.23
ESS 0.062 0.56 −0.139 0.20
LEDD −0.327 0.001 0.258 0.009
NMSS Non Motor Symptom Scale, LEDD levodopa equivalent dose, PDSS
Parkinson’s disease sleep scale, HADS hospital and anxiety depression scale,
MMSE mini mental state examination, ESS Epworth’s sleepiness scale, BKS
bradykinesia score, DKS dyskinesia score
aThe miscellaneous domain contains questions about pain, hyposmia,
hyperhidrosis and weight change
Signiﬁcant values are highlighted in bold
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speciﬁc items in domains 4, 6 and 9 included as independent
variables. In this model, NMSS items 9 (anxiety; β=−0.296, p=
0.008), 14 (delusions; β= 0.400, p= 0.001), 20 (dysphagia; β=
−0.278, p= 0.005), 28 (hyposmia; β= 0.187, p= 0.032), 29 (weight
change; β= 0.205, p= 0.027) and 30 (hyperhidrosis; β= 0.273,
p= 0.004) were found to be signiﬁcant predictors of DKS.
In order to control for the possible effect of NMS changes over
time, we performed a separate analysis for patients who had the
start of the PKG recording taking place within 30 days of their
clinical assessment (n= 80). This model (adjusted R2= 0.484, SE=
10.89), in line with the ﬁndings from the total cohort, showed that
DKS was predicted by NMSS domain 3 (mood/cognition; β=
−0.520, p < 0.001), NMSS domain 4 (perceptual problems/halluci-
nations; β= 0.282, p= 0.010), NMSS domain 9 (miscellaneous; β=
0.215, p= 0.045) and LEDD (β= 0.347, p= 0.002).
DISCUSSION
This study addressed the impact of wearable sensor monitoring
on the assessment of NMS. The main ﬁnding in our exploratory
analyses revealed that PKG BKS scores were associated with low
LEDD, constipation and the sexual domain scores of the NMSS. In
addition, DKS scores on PKG correlated with high LEDD, mood and
cognition, perceptual problems, constipation and the miscella-
neous symptom domain of the NMSS. These results support the
concept that wearable sensor use may potentially serve as a
marker for some key NMS in PD.14,15
The relationship between LEDD and BKS supports the concept
of BKS being a key hypo-dopaminergic symptom of PD further
supported by the fact that lower LEDD was associated with worse
BKS and SCOPA motor scores. These ﬁndings support previous
studies showing the usefulness of PKG in reﬂecting BKS in patients
and that increasing dopaminergic medication may thus reduce
BKS, a clinically known phenomenon.6 Clinically, these data thus
support the use of PKG to optimise medication regimes in
‘undertreated’ patients as has also been recently reported.16
However, of key interest is the fact that we report that
constipation, regarded as a NMS of gastrointestinal dysfunction4
and sexual dysfunction is in general associated with higher BKS
scores. Large-scale studies are still required to further investigate
this relationship. The clinical impact could be that high BKS scores
on the PKG should prompt clinicians to enquire about and address
gastrointestinal symptoms in their patients. Previous studies have
shown that 43.5% of gastrointestinal symptoms are unreported by
patients; possible reasons include a lack of understanding that
these symptoms are related to PD, embarrassment to disclose
these symptoms and clinic time being focused on the discussion
of motor symptoms instead.5 Identifying possible non-motor
surrogate markers of the PKG could beneﬁt wider clinical practice
in this way.
DKS, on the other hand, was related to high LEDD, consistent
with DKS being a hyper-dopaminergic symptom and has been
well described in relation to PKG use.17,18 Interestingly, high DKS
scores were associated with euphoria and increased perceptual
problems and hallucinations.17,18 Such an occurrence is in line
with evidence suggesting that excessive dopaminergic stimulation
in the mesocortical and mesolimbic dopaminergic pathways
results in elevated mood and euphoria, as well as psychotic
symptoms such as delusions and hallucinations.19
This study underlines a pivotal unmet need in PD in that
accurate and objective assessment of NMS is still lacking. One can
argue that the results from our study can be replicated through
careful history taking for example by speciﬁcally asking about
constipation in patients who are very bradykinetic. However,
current assessments of NMS in PD, but also of motor symptoms,
and subsequent treatment decisions continue to suffer from
inaccuracies related to clinical scales as well as recall bias and
retrospective data entry for diaries.20 Using wearable sensors may
address part of this problem and surely needs further exploration,
even though, in the long term, wearable sensor use may not
emerge as a robust marker for the heterogeneous NMS of PD.
There are of course limitations in this work. While the PKG
assessments were based on a 6-day recording, the non-motor
assessments included in the regression model were only
completed at one point in time. Like the motor symptoms, these
NMS also ﬂuctuate18 and may not provide an accurate depiction
of the duration, severity and course of the symptoms. Moreover,
patient-based assessments are prone to subjectivity and recall bias
and clinician-based assessments are prone to inter-rater variability.
In addition, not all participants in the NILS study had a PKG
reading close to their assessment date. We matched the PKG
reading to the closest NILS assessment, selecting an arbitrary cut-
off of 4 months. The NMS, and also the LEDD, may have improved
or worsened during these 4 months. When we, however, analysed
the group of patients who had a PKG recording within 30 days of
their clinical assessment, we did not ﬁnd differences in the main
outcomes, making it unlikely that the longer-time PKG and clinical
assessment have inﬂuenced our results. Finally, it might be argued
that our ﬁndings were driven by disease duration as a confounder.
However, a separate analysis showed none of the studied NMS to
be associated with disease duration.
In summary, gastrointestinal function (particularly constipation)
was signiﬁcantly associated with BKS scores of PKG, providing
evidence that the PKG could be used to monitor non-motor
outcomes, such as constipation. Although the observation that,
e.g., constipation is linked to general BKS is not novel, this study
shows that motor outcomes obtained through wearable sensors
are associated with such NMS. This suggests that further work
should be undertaken to explore the role of wearable sensors to
be used as markers of speciﬁc NMS in PD.
METHODS
Patient cohort
All consecutive patients between July 2014 and February 2018 with a
diagnosis of probable idiopathic PD who participated in the Non-motor
Longitudinal International Study (NILS) and had a baseline assessment
were included in the study. The NILS cohort study (adopted as a national
study by the National Institute of Health Research in the United Kingdom
(UKCRN No. 10084)) is a comprehensive study with non-motor proﬁling of
PD as the primary outcome measure addressing natural history of NMS,
treatment response and clinico-pathological-imaging correlations. For this
analysis, only patients who had an assessment at King’s College Hospital
were included. The NILS study was authorised by local ethics committees
(NRES South East London REC, 10084, 10/H0808/141). All patients gave
written consent prior to study procedures in accordance with the
Declaration of Helsinki. PKG readings were performed as part of standard
clinical care after the device was granted licence in the United Kingdon
from 2016. All patient data were anonymised and coded. The project was
also under the data protection act code of the General Data Protection
Regulation (2016/679 EU) (GDPR).
Data collection
Data extracted from the NILS database concerned sex, disease onset (in
years), Hoehn and Yahr stage, levodopa equivalent dose (LEDD), Scales for
Outcomes in Parkinson’s Disease (SCOPA) motor, NMS Scale (NMSS),21
Hospital Anxiety and Depression Scale (HADS),22 Parkinson Disease Sleep
Scale (PDSS),23 Epworth Sleepiness Scale (ESS)24 and Mini Mental State
Examination (MMSE) scores.25 The NMSS has 30 items and nine domains:
cardiovascular (2 items), sleep/fatigue (4 items), mood/cognition (6 items),
perceptual problems/hallucinations (3 items), attention/memory (3 items),
gastrointestinal tract (3 items), urinary function (3 items), sexual function (2
items) and miscellaneous (4 items). Each item scores on a multiple of severity
(from 0 to 3) and frequency scores (from 1 to 4) and the theoretical range of
the NMSS total score is 0–360. The NMSS domains were deﬁned as follows:
cardiovascular and falls (domain 1), sleep/fatigue (domain 2), mood/cognition
(domain 3), perceptual problems/hallucinations (domain 4), attention/
memory (domain 5), gastrointestinal tract (domain 6), urinary (domain 7),
D.J. van Wamelen et al.
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sexual function (domain 8) and miscellaneous (domain 9). The aforemen-
tioned scales and outcomes were performed during the ON-state in patients.
The PKG output provided the BKS and DKS data for each patient. The
PKG system consists of a data logger containing a rechargeable battery, a
triaxial accelerometer and memory to store data, and it is worn on the wrist
of the most affected side. The PKG is worn continuously for six consecutive
days, after which data are downloaded and analysed by using a proprietary
algorithm to calculate the BKS and DKS scores. The BKS score is the median
value of BKS scores over the period from 05:00 to 21:00 of each recorded
day and BKS correlates with UPDRS III scores. The DKS score is the median
value of DKS over the period from 05:00 to 21:00 of each recorded day and
the score correlates with the modiﬁed Abnormal Involuntary Movement
Score assessed at the time of PKG.6,26 Baseline values for BKS and DKS are
18.6 and 4.3, respectively.8 Optimal control in PD is deﬁned as a BKS score
of 23 or less and a DKS score of 7 or less, whereas poor control is deﬁned
by a BKS score of 25 or higher and a DKS score of 9 or above.8
All patients participating in the NILS study (n= 386) for whom a 6-day
PKG reading was available between July 2014 and February 2018 were
assessed for inclusion into the study (n= 144). A total of 108 participants
were identiﬁed with a PKG reading within 4 months of their NILS
assessments and fulﬁlling all other criteria (Fig. 1).
Outcome measures and statistical analysis
The primary outcome in the study was to assess whether the PKG
measures BKS and DKS are associated with NMS. The secondary outcome
was to explore which of the NMS domains were associated with BKS and
DKS outcomes. For these, we used multiple linear regression with BKS or
DKS as dependent variables and with PD demographics (age at onset,
disease duration and LEDD), NMSS domains 1–9, PDSS, MMSE, HADS and
ESS scores as independent variables. Data are presented as mean ±
standard deviation or percentage when appropriate. All data were
analysed by using SPSS Version 24 (IBM SPSS Statistics for Windows,
Version 24.0, Armonk, NY: IBM Corp.).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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